These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 38829559

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ, Dai XY, Qiu Y, Liu XN, Zeng CM, Xu XY, Chen YD, Zhu H, He QJ, Gai RH, Ma SL, Chen XQ, Yang B.
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [Abstract] [Full Text] [Related]

  • 3. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
    Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, Bergman B, Djos A, Chen N, Martinsson T, Van den Eynden J, Doebele RC, Palmer RH, Hallberg B, Umapathy G.
    Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
    de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.
    J Thorac Oncol; 2014 Feb; 9(2):248-53. PubMed ID: 24419423
    [Abstract] [Full Text] [Related]

  • 8. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
    Lingling X, Maoxi C, Wei Y, Jieting Z, Yuanyuan Y, Ning X.
    Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
    [Abstract] [Full Text] [Related]

  • 9. [Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation 
Treated with Ensartinib: A Case Report and Literature Review].
    Lv D, Xu C, Wang C, Sang Q.
    Zhongguo Fei Ai Za Zhi; 2023 Jan 20; 26(1):78-82. PubMed ID: 36792084
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ, Kim HR, Shim HS.
    J Transl Med; 2016 Oct 19; 14(1):296. PubMed ID: 27756333
    [Abstract] [Full Text] [Related]

  • 11. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 19; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
    Yang C, Zeng R, Zha Y, Li Y, Wang T, Zhao R, Li M, Zhang J.
    Front Immunol; 2024 Mar 19; 15():1360671. PubMed ID: 38380327
    [Abstract] [Full Text] [Related]

  • 15. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP, Pathi N, Viswanath S, Rathore A, Pathak A, Sud R.
    Indian J Cancer; 2017 Mar 19; 54(1):203-208. PubMed ID: 29199691
    [Abstract] [Full Text] [Related]

  • 16. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.
    J Thorac Oncol; 2019 Jul 19; 14(7):1233-1243. PubMed ID: 30902613
    [Abstract] [Full Text] [Related]

  • 17. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H, Yasugi M, Takigawa N, Hotta K, Ichihara E, Taniguchi A, Toyooka S, Hashida S, Sendo T, Tanimoto M, Kiura K.
    Jpn J Clin Oncol; 2014 Oct 19; 44(10):963-8. PubMed ID: 25170107
    [Abstract] [Full Text] [Related]

  • 18. ALK fusion small cell transformation of lung adenocarcinoma: A case report and literature review.
    Xu G, Zhou L.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Apr 28; 49(4):628-636. PubMed ID: 39019792
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.